Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 218 clinical trials
featured
Metastatic Colorectal Cancer with wild-type KRAS tumors.

Metastatic Colorectal Cancer with wild-type KRAS tumors.

  • 204 views
  • 25 Mar, 2021
  • 1 location
Donafenib for Previously Treated Metastatic Colorectal Cancer

The investigators do the clinical trial (patients with metastatic colorectal cancer treated with donafenib/placebo after failure of standard therapy) to assess efficacy and safety of donafenib

kidney function tests
bevacizumab
oxaliplatin
adenocarcinoma of colon
irinotecan
  • 0 views
  • 03 Jun, 2021
  • 2 locations
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

patients with PIK3CA mutated metastatic colorectal cancer.

fluorouracil
metastasis
oxaliplatin
PIK3CA
adenocarcinoma of colon
  • 2 views
  • 27 Jan, 2021
  • 39 locations
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

This study is designed to primarily evaluate the safety and efficacy of U3-1402 in participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2 prior lines of

neutrophil count
vascular endothelial growth factor
oxaliplatin
liver metastasis
irinotecan
  • 0 views
  • 13 Feb, 2021
  • 43 locations
  • 0 views
  • 13 Jun, 2021
  • 64 locations
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

The FIRE-4 study aims to define a treatment concept for patients with RAS wild-type tumours, optimised with regard to overall survival. The first-line treatment will be conducted with FOLFIRI plus cetuximab, which resulted in a significantly prolonged overall survival versus bevacizumab in the FIRE-3 study. Following initial progression (PD1) it …

neutrophil count
liver metastasis
irinotecan
KRAS
capecitabine
  • 6 views
  • 21 Jan, 2021
  • 1 location
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

together with combination chemotherapy with or without capecitabine followed by bevacizumab maintenance therapy in treating patients with metastatic colorectal cancer that cannot be removed by

fluorouracil
bevacizumab
leucovorin
irinotecan
calcium
  • 7 views
  • 07 Nov, 2020
  • 1 location
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer

effectiveness of CMAB009 in combination with a standard and effective chemotherapy FOLFIRI5-Fluorouracil /Folinic acid plus Irinotecanfor RAS/BRAF wild-type, metastatic colorectal cancer in first-line setting

fluorouracil
folfiri regimen
metastasis
leucovorin
BRAF
  • 3 views
  • 25 Jan, 2021
  • 2 locations
A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer

This is a randomized, open-label, multi-center, phase III study of Napabucasin plus bi-weekly FOLFIRI (Arm 1) vs. Napabucasin (Arm 2) for adult patients with metastatic CRC who have failed standard chemotherapy regimens. For patients who have failed bevacizumab with irinotecan-based chemotherapies (treatment failure is defined as radiologic progression of disease …

  • 27 views
  • 23 Jan, 2021
  • 37 locations
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Compare the objective remission rate of A140 and Erbitux combined with mfolfox6 regimen in the first-line treatment of Ras wild-type metastatic colorectal cancer for 12 weeks

  • 0 views
  • 19 Apr, 2021
  • 1 location